A wide range of neuropsychiatric (NP) manifestations has been described in systemic lupus erythematosus (SLE), which include common features such as headache, mood disorders and cognitive dysfunction to rarer events such as seizures, psychosis and myelopathy. [1] [2] [3] [4] [5] The reported prevalence of NP disease in patients with SLE has varied from 37% to 95% 1-7 and the prognosis following an NP event has also varied considerably. For example, several studies have reported an increased mortality associated with NP events attributed to SLE (NPSLE), [8] [9] [10] [11] whereas others have refuted this. [12] [13] [14] The discrepant results may be due to differences in research methodology, bias in the selection of patients for study or a temporal transition in disease severity. Previous studies of prognosis in NPSLE have been hampered by a number of factors including: 1) lack of standardised definitions/criteria for NP events; 2) failure to use standardised/validated instruments to measure important outcomes such as cumulative organ damage and quality of life; 3) retrospective study design limited to single academic medical centres.
Classification of NPSLE
Although several arbitrary classifications of NPSLE have been developed, most are hindered by lack of definitions for individual manifestations and lack of standardisation for investigation and diagnosis. In 1999, the American College of Rheumatology (ACR) research committee produced a standard nomenclature and set of case definitions for 19 NP syndromes, 15 which may be used to characterise NP events ( Table 1 ). For each of these NP syndromes, potential aetiologies other than SLE were identified by the ACR for either exclusion or recognised as an 'association'. This component of the ACR classification, in combination with other variables, provides a mechanism for determining the attribution of NP events.
Aetiology of NPSLE
NPSLE are primary manifestations of the disease, as opposed to a result of complications of the disease (e.g., hypertension), or its therapy (e.g., infection), or a concurrent non-SLE-related NP event ( Figure 1 ). Current evidence suggests that NPSLE is a consequence of vascular abnormalities, in particular a non-inflammatory microangiopathy associated with cerebral infarction, autoantibodies and the local production of inflammatory mediators such as various cytokines and matrix metalloproteinases. 16 Antiphospholipid and anti-ribosomal P antibodies have shown the strongest clinical correlation with NP disease, 16 whereas the more recently described anti-NR2 glutamate receptor antibody 17 is novel and of potential interest. All three families of autoantibodies merit further investigation. In view of the central role of the blood-brain barrier in protecting the brain from circulating autoantibodies, 18 an indicator of its permeability should be incorporated into future studies of immune-mediated injury in NPSLE.
Thus, NPSLE represents a major challenge for clinicians, in view of the uncertainties surrounding the pathogenesis, diagnosis and treatment. It is clear that the issue of NP disease in patients with SLE requires further study. The NPSLE systemic lupus international collaborating clinics (SLICC) inception cohort study has been designed to specifically evaluate this subset of SLE and addresses methodological deficiencies of previous studies.
The systemic lupus international collaborating clinics
The SLICC research network was formed in 1987 19 and currently consists of 30 investigators in 27 international centres in eight countries. Amongst other initiatives, SLICC has developed and validated instruments for use in clinical studies of SLE. [20] [21] [22] [23] [24] [25] [26] [27] In 2002, SLICC commenced enrolment into the NPSLE SLICC inception cohort to prospectively study the clinical features, clinical outcomes and pathogenic mechanisms of nervous system disease in patients with SLE. The NPSLE SLICC study is con-ducted in parallel and in conjunction with the SLICC Atherosclerosis Registry designed to investigate the issue of atherosclerosis in SLE. 28 Enrolment in the NPSLE SLICC study has continued steadily and is presently 1260 patients. The cohort is predominantly women (89%), with a mean (±SD) age of 34.1 ± 13.2 years and a wide ethnic distribution. At enrolment, the mean disease duration is 5.4 ± 4.2 months.
NP events are classified using the ACR nomenclature and case definitions. 15 For all NP events, a list of potential aetiological factors other than SLE are identified for exclusion or recognised as an 'association'. 15 Collectively, these are referred to as 'non-SLE factors' and have been used in part to determine the attribution of NP events. Decision rules to determine the attribution of NP events take into account the following factors: 1) time of onset of NP event(s) in relation to the diagnosis of SLE; 2) presence of concurrent 'non-SLE factor(s)' thought to be a cause or significant contributor to the event; 3) occurrence of 'minor' NP events shown by Ainiala, et al. to have a high frequency in normal population controls. 1 These latter NP manifestations included all headaches, anxiety, mild depression (mood disorders that fail to meet the criteria for 'major depressive-like episodes'), mild cognitive impairment (deficits in less than three of eight cognitive domains specified in the ACR case definitions) and polyneuropathy without electrophysiological confirmation.
Two sets of decision rules of different stringency 29 have been used to determine the attribution of NP events. Those which fulfilled the criteria for model A (the most stringent) or for model B (the least stringent) were attributed to SLE. NP events that did not fulfil these criteria were attributed to non-SLE causes. Using these decision rules, the proportion of NP events at enrolment that were attributed to SLE varied from 19% (model A) to 38% (model B) and affected 6.1% (model A) to 11.7% (model B) of patients. In both attribution models, a total of 13 (68%) of the 19 NP syndromes were identified of which seizure disorders, cerebrovascular disease, acute confusional states and neuropathies were the most common NP events attributed to SLE.
Three complementary studies have been completed using data from the enrolment assessment of the NPSLE SLICC inception cohort [29] [30] [31] and provide the basis for a long-term prospective study: 1) NP events: health-related quality of life (HRQOL), disease activity and organ damage: 29 SLE patients with NP events, regardless of attribution, had consistently lower mean scores on SF-36 subscales (P < 0.05), physical (P < 0.05) and mental (P < 0.001) component summary scores indicating a lower HRQOL. The results were similar after adjustment for age at diagnosis, race, education and SLEDAI score. The association between global disease activity (SLEDAI) and NP disease was not significant. However, cumulative organ damage (SLICC/ACR DI) was significantly higher in patients with NP events compared with those without NP events (mean ± SD: 0.65 ± 1.10 vs 0.29 ± 0.66, P = 0.004) and was also higher in patients with NP events attributed to SLE compared with non-SLE causes using attribution model A (1.29 ± 1.57 vs 0.42 ± 0.77, P < 0.001) or model B (1.06 ± 1.37 vs 0.24 ± 0.50, P < 0.001). Thus, NP events at diagnosis of SLE are associated with reduced HRQOL and increased organ damage. 2) NP events: short-term outcomes assessed by physicians and patients: 31 The short-term outcomes of NP events as assessed by physicians and patients were examined and compared. Physiciangenerated outcome scores were measured on a Likert scale and patient assessment of outcome was determined by the mental (MCS) and physical (PCS) component summary scores of the SF-36. Patients with NP events attributed to SLE had significantly better physician outcome scores compared with patients with NP events attributed to non-SLE causes (P < 0.001). Lower (worse) MCS scores were seen in patients with diffuse compared with focal (P < 0.002) and with central compared with peripheral (P < 0.02) NP events. Only in patients with NP events attributed to SLE, there was a significant association between physician and patient assessments of outcome (P < 0.001). Thus, the short-term outcome of NP events is determined by their characteristics and attribution. NP events attributed to SLE have a better shortterm outcome and there is agreement between physician and patient assessments of outcome of these NP events. 3) NP events: association with autoantibodies: 30 The association of antiphospholipid (lupus anticoagulant, anticardiolipin), anti-β2-GPI, antiribosomal P and anti-NR2 glutamate receptor antibodies with NP events around the time of diagnosis of SLE was examined. All autoantibodies were measured in Dr Joan Merrill's laboratory at the Oklahoma Medical Research Foundation. There was no association between autoantibodies and NP events from all causes. However, anti-ribosomal P antibodies were associated with central NP (P = 0.04) and diffuse NP (P = 0.02) events attributed to SLE (attribution model A) compared with NP events attributed to other causes and no NP events. A specific clinical-serological association was found between anti-ribosomal P and psychosis (P = 0.02). Moreover, an association was also reported between lupus anticoagulant and cerebrovascular disease (P = 0.04) attributed to SLE. There was no significant association between NP events, anticardiolipin, anti-β2 glycoprotein-I and anti-NR2 glutamate receptor antibodies. Thus, clinically distinct NP events (psychosis and cerebrovascular disease) attributed to SLE at disease inception are associated with either anti-ribosomal P antibodies or lupus anticoagulant, suggesting separate autoimmune pathogenic mechanisms. Although there was no association with other autoantibodies, this does not preclude subsequent associations over time between these autoantibodies and NPSLE. Factors such as persistent 32, 33 or relative increase 34, 35 in autoantibody production or enhanced permeability of the blood-brain barrier 18 may be required for the occurrence of clinical events in these cases. Further work is required to address these possibilities.
In summary, a large, international, multi-ethnic, inception cohort of patients with SLE has been established and a standardised approach to the diagnosis, classification and attribution of all NP events has been systematically applied. In a series of cross-sectional studies, the clinical significance, short-term outcome and autoantibody associations of NP events around the time of diagnosis of SLE have been examined. There is evidence of an adverse impact on healthrelated quality of life and an association with increased organ damage early in the disease course. Furthermore, the outcome of NP events varies according to their characteristics and attribution, and there is agreement between physician and patient assessments of the short-term outcome of NP events attributed to SLE. Finally, studying a panel of autoantibodies that are historically relevant to NPSLE, the finding of two distinct clinical-serological associations indicates different autoimmune pathogenic mechanisms, already evident early in the course of the disease. Further follow-up of this unique inception cohort of patients with SLE for up to 10 years will determine the full spectrum and frequency of nervous system disease in patients with SLE over time, the long-term outcome and impact of clinical events and provides an opportunity to elucidate the role of autoantibodies and other pathogenetic mechanisms in NPSLE.
